[go: up one dir, main page]

FR2856686A1 - Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation - Google Patents

Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation

Info

Publication number
FR2856686A1
FR2856686A1 FR0307648A FR0307648A FR2856686A1 FR 2856686 A1 FR2856686 A1 FR 2856686A1 FR 0307648 A FR0307648 A FR 0307648A FR 0307648 A FR0307648 A FR 0307648A FR 2856686 A1 FR2856686 A1 FR 2856686A1
Authority
FR
France
Prior art keywords
diones
benzothiazole
derivatives
benzooxazole
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR0307648A
Other languages
English (en)
Inventor
Contour Marie Odile Galcera
Olivier Lavergne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority to FR0307648A priority Critical patent/FR2856686A1/fr
Priority to PCT/FR2004/001578 priority patent/WO2005000843A2/fr
Priority to AU2004251912A priority patent/AU2004251912A1/en
Priority to MXPA06000217A priority patent/MXPA06000217A/es
Priority to US10/562,949 priority patent/US7335674B2/en
Priority to CA002530662A priority patent/CA2530662A1/fr
Priority to BRPI0411871-5A priority patent/BRPI0411871A/pt
Priority to EP04767434A priority patent/EP1641789A2/fr
Priority to CNA2004800243949A priority patent/CN1842522A/zh
Priority to KR1020057024694A priority patent/KR20060024814A/ko
Priority to JP2006516315A priority patent/JP2007515383A/ja
Priority to RU2006101980/04A priority patent/RU2006101980A/ru
Priority to ARP040102256A priority patent/AR044929A1/es
Publication of FR2856686A1 publication Critical patent/FR2856686A1/fr
Priority to IL172774A priority patent/IL172774A0/en
Priority to NO20060124A priority patent/NO20060124L/no
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)

Abstract

L'invention a pour objet un procédé de préparation orienté de dérivés de benzothiazole-4,7-diones et de benzoxazole-4,7-diones monosubstitués en position 5 ou en position 6 par un groupe amino lui-même éventuellement substitué. Lesdits dérivés sont des inhibiteurs des phosphatases Cdc25 et peuvent être utilisés pour préparer des médicaments destinés à traiter le cancer.L'invention offre aussi des intermédiares de synthèse utiles dans la mise en oeuvre du procédé de l'invention.L'invention concerne aussi les dérivés de benzothiazole-4,7-diones suivants :- 2-(2-chloro-6-fluorophényl)-5-{[2-(diméthylamino)éthyl]amino}-1,3-benzothiazole-4,7-dione ;- 2-(2-chloro-6-fluorophényl)-5-[(2-pyrrolidin-1-yléthyl)amino]-1,3-benzothiazole-4,7-dione.
FR0307648A 2003-06-25 2003-06-25 Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation Pending FR2856686A1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
FR0307648A FR2856686A1 (fr) 2003-06-25 2003-06-25 Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
EP04767434A EP1641789A2 (fr) 2003-06-25 2004-06-24 Benzothiazole-4,7-diones et benzoxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
CNA2004800243949A CN1842522A (zh) 2003-06-25 2004-06-24 在5或6位具有取代基的苯并噻唑－4,7－二酮与苯并噁唑－4,7－二酮和它们的制备方法
MXPA06000217A MXPA06000217A (es) 2003-06-25 2004-06-24 Benzotiazol-4,7-dionas y benzoxazol-4,7-dionas con sustituyentes en la posicion 5 o 6 y procedimiento para su preparacion.
US10/562,949 US7335674B2 (en) 2003-06-25 2004-06-24 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof
CA002530662A CA2530662A1 (fr) 2003-06-25 2004-06-24 Benzothiazole-4,7-diones et benzoxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
BRPI0411871-5A BRPI0411871A (pt) 2003-06-25 2004-06-24 processo de preparação de um composto, composto e utilização de um composto
PCT/FR2004/001578 WO2005000843A2 (fr) 2003-06-25 2004-06-24 Benzothiazole-4,7-diones et benzoxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
AU2004251912A AU2004251912A1 (en) 2003-06-25 2004-06-24 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof
KR1020057024694A KR20060024814A (ko) 2003-06-25 2004-06-24 5 위치 또는 6 위치에 치환기를 갖는 벤조티아졸-4,7-디온및 벤즈옥사졸-4,7-디온 및 이들의 제조 방법
JP2006516315A JP2007515383A (ja) 2003-06-25 2004-06-24 ５又は６位で置換されたベンゾチアゾール−４，７−ジオン及びベンゾオキサゾール−４，７−ジオン並びにその製造方法
RU2006101980/04A RU2006101980A (ru) 2003-06-25 2004-06-24 Бензотиазол-4, 7-дионы и бензоксазол-4, 7-дионы, замещенные в положении 5 или 6 и способы их получения
ARP040102256A AR044929A1 (es) 2003-06-25 2004-06-25 Benzotiazol- 4,7 - dionas y benzoxazol -4,7- dionas sustituidas en la posicion 5 o 6 y procesos para su preparacion
IL172774A IL172774A0 (en) 2003-06-25 2005-12-22 Benzothiazole-4, 7-diones and benzoxazole-4, 7-diones with substituents in positions 5 or 6 and method for production thereof
NO20060124A NO20060124L (no) 2003-06-25 2006-01-09 Benzotiazol-4,7-Dioner og Benzoksazol-4,7-Dioner med Substituenter i 5- eller 6-stilling og metoder for deres fremstilling

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0307648A FR2856686A1 (fr) 2003-06-25 2003-06-25 Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation

Publications (1)

Publication Number Publication Date
FR2856686A1 true FR2856686A1 (fr) 2004-12-31

Family

ID=33515381

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0307648A Pending FR2856686A1 (fr) 2003-06-25 2003-06-25 Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation

Country Status (15)

Country Link
US (1) US7335674B2 (fr)
EP (1) EP1641789A2 (fr)
JP (1) JP2007515383A (fr)
KR (1) KR20060024814A (fr)
CN (1) CN1842522A (fr)
AR (1) AR044929A1 (fr)
AU (1) AU2004251912A1 (fr)
BR (1) BRPI0411871A (fr)
CA (1) CA2530662A1 (fr)
FR (1) FR2856686A1 (fr)
IL (1) IL172774A0 (fr)
MX (1) MXPA06000217A (fr)
NO (1) NO20060124L (fr)
RU (1) RU2006101980A (fr)
WO (1) WO2005000843A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
ATE368654T1 (de) * 2001-12-27 2007-08-15 Sod Conseils Rech Applic Benzothiazol- und benzoxazol-4,7-dionderivate und ihre verwendung als cdc25-phosphatasen- inhibitoren
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2877667B1 (fr) 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
FR2945532A1 (fr) * 2009-05-15 2010-11-19 Ipsen Pharma Sas Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25
BR112019007271A2 (pt) * 2016-10-10 2019-09-17 Dev Ct Biotechnology compostos de quinoxalina como inibidores do receptor da tirosina quinase do tipo iii

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096348A2 (fr) * 2001-05-30 2002-12-05 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Produit comprenant du mikanolide ou du dihydromikanolide en association avec un autre agent anti-cancereux
WO2003055868A1 (fr) * 2001-12-27 2003-07-10 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives de benzothiazole- et benzoxazole-4,7-diones et leur utilisation comme inhibiteurs de phosphatases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096348A2 (fr) * 2001-05-30 2002-12-05 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Produit comprenant du mikanolide ou du dihydromikanolide en association avec un autre agent anti-cancereux
WO2003055868A1 (fr) * 2001-12-27 2003-07-10 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives de benzothiazole- et benzoxazole-4,7-diones et leur utilisation comme inhibiteurs de phosphatases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RYU C-K C-K ET AL: "5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 5, March 2000 (2000-03-01), pages 461 - 464, XP004202438, ISSN: 0960-894X *

Also Published As

Publication number Publication date
RU2006101980A (ru) 2006-07-27
US20060135573A1 (en) 2006-06-22
JP2007515383A (ja) 2007-06-14
WO2005000843A2 (fr) 2005-01-06
US7335674B2 (en) 2008-02-26
BRPI0411871A (pt) 2006-08-08
AU2004251912A1 (en) 2005-01-06
WO2005000843A3 (fr) 2005-05-26
NO20060124L (no) 2006-01-20
IL172774A0 (en) 2006-04-10
CN1842522A (zh) 2006-10-04
KR20060024814A (ko) 2006-03-17
AR044929A1 (es) 2005-10-12
EP1641789A2 (fr) 2006-04-05
CA2530662A1 (fr) 2005-01-06
MXPA06000217A (es) 2006-04-11

Similar Documents

Publication Publication Date Title
DE60019964D1 (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide als inhibitoren cyclinabhängiger kinasen
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
MA28064A1 (fr) Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases
TNSN98203A1 (fr) Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant
TNSN00228A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
MY138352A (en) Benzothiazole derivatives
MY125768A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
GEP20043367B (en) N-[5-[[[5-Alkyl-2-Oxazolyl]Methyl]Thio]-2-Thiazolyl Carboxamide Inhibitors of Cyclin Dependent Kinases
MA27933A1 (fr) Inhibiteurs de l'activite de akt
TNSN00028A1 (fr) Derives de quinoleine -2-one a substituant heteroaryle nouveaux procede pour leur preparation et compositions pharmaceutiques les contenant.
EP1641748A4 (fr) Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer
EP1643986A4 (fr) Inhibiteurs de la beta-secretase de phenylcarboxylate destines au traitement de la maladie d'alzheimer
EP1758854A4 (fr) Composes pyrrolidin-3-yle utiles en tant qu'inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
EP1804794A4 (fr) Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer
MA35090B1 (fr) Polythérapie pour les malignités hématologiques
TNSN06109A1 (fr) Derives [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine
DE69113155D1 (de) 17-beta-substituierte-4-aza-5-alpha-androstan-3-one-derivate und verfahren zu ihrer herstellung.
FR2856686A1 (fr) Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
RU2003128312A (ru) Производные эпотилона, используемые для лечения резистентных опухлей
EP1807396A4 (fr) Composes de 2-aminopyridine utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
MA28429B1 (fr) Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases
MA27066A1 (fr) 6,7-DIHYDRO-5H-PYRAZOLO[1,2-A]PYRAZOL-1-ONES CONTRôLANT LES CYTOKINES INFLAMMATOIRES.
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
IL178167A0 (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators
MA26117A1 (fr) Nouveau compose pour le traitement de l'impuissance